Chemo and SBRT for Inoperable Pancreatic Cancer
For inoperable pancreatic cancer, researchers are comparing mFOLFIRINOX and SBRT with gemcitabine-based treatment regimens.
Testing an Approved Drug for a Specific Mutation
Researchers are testing a drug combination for melanoma in pancreatic cancer patients with a BRAF genetic mutation.
Time and Hope
Rose farmer Michael Francis wanted more time with his family, so he joined a clinical trial to treat his stage III pancreatic cancer.
Safety and Effectiveness of a New Drug for Advanced Pancreatic Cancer
Researchers are testing dose safety and effectiveness of a new drug for pancreatic cancer, in combination with gemcitabine.
Standard Chemotherapy Plus Novel Drugs for Advanced Pancreatic Cancer
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Chemotherapy Plus Minimally Invasive Surgery for Pancreatic Cancer
Researchers want to know if irreversible electroporation (IRE) makes it easier for chemotherapy to reach pancreatic cancer cells.
Combining Two Drugs with Different Approaches to Enhance Treatment
A clinical trial combines epigenetic therapy and immunotherapy to make immunotherapy more effective for patients with pancreatic and bile duct cancers.
Drug Combination to Combat Pancreatic and other Gastrointestinal Cancers
Researchers are testing a drug combination of TAS-102, an approved drug for colorectal cancer, and nanoliposomal irinotecan, on gastrointestinal cancers.
Immunotherapy to Attack a Common Pancreatic Cancer Mutation
Researchers are testing a type of immunotherapy to attack a variant of the KRAS mutation; KRAS mutations occur in almost all pancreatic cancers.
Immunotherapy for Advanced Pancreatic Cancer and Other Solid Tumors
Researchers are testing the use of tumor-infiltrating lymphocytes, a type of immunotherapy, against advanced pancreatic cancer.
Immunotherapy to Enhance Standard Chemotherapy for Advanced Pancreatic Cancer
Researchers are testing an immunotherapy drug approved for other advanced cancers for effectiveness against pancreatic cancer.
Testing a Different Approach to Pancreatic Cancer Treatment
A drug that is epigenetic therapy, which alters how DNA behaves, is being tested in a clinical trial for pancreatic cancer.
The Positive Impact of a Pancreatic Cancer Clinical Trial
Richard Blish was a healthy, athletic 67-year-old when he developed symptoms of pancreatic cancer. His daughter steered him to a clinical trial for treatment.